Jacqueline Saw1, Esben Hjorth Madsen2, Sammy Chan2, Elisabeth Maurer-Spurej3. 1. Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: jsaw@interchange.ubc.ca. 2. Canadian Blood Services, Vancouver, British Columbia, Canada. 3. Department of Pathology and Laboratory Medicine and Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada; Canadian Blood Services, Vancouver, British Columbia, Canada; Division of Cardiology, St. Paul's Hospital, Vancouver, British Columbia, Canada.
Abstract
OBJECTIVES: This study was designed to evaluate the effects of long-term clopidogrel and aspirin administration on platelet aggregation, activation, and inflammation. BACKGROUND: Clopidogrel resistance was described in 15% to 30% of patients with short-term therapy, but its antiplatelet effects with long-term therapy is unknown. METHODS: We performed a prospective study of patients undergoing coronary stenting who were on aspirin for > or =5 days but not previously on clopidogrel. Clopidogrel 600 mg was given before stenting. Clopidogrel 75 mg/day and aspirin 325 mg/day were continued for 1 year. Light-transmittance aggregometry with 5-micromol/l adenosine diphosphate and 1-mmol/l arachidonic acid stimulation; VerifyNow clopidogrel and aspirin assays; platelet activation receptor expression of CD40L, CD62P, and PAC-1 (antibody against activated glycoprotein IIb/IIIa); and inflammatory markers of soluble CD40L and P-selectin, high-sensitivity C-reactive protein, interleukin-10, and interleukin-18 were measured at baseline; 1 day; and 1, 6, and 12 months. Our primary analysis compared light-transmittance aggregometry aggregation at 1 versus 12 months. RESULTS: We enrolled 26 patients who completed a 1-year follow-up. Maximal platelet adenosine diphosphate-stimulated aggregation was 61.8 +/- 25.9% at baseline, 22.1 +/- 18.3% at 1 day, 30.6 +/- 16.8% at 1 month, 29.0 +/- 13.3% at 6 months, and 26.7 +/- 13.6% at 12 months (p = 0.099 for 12 months vs. 1 month). VerifyNow clopidogrel platelet inhibition was similar at 12 months versus 1 month (38.9 +/- 19.7% vs. 45.6 +/- 26.7%, p = 0.578). Likewise, there was no difference in aspirin's effects on platelet aggregation at 12 months versus 1 month. In contrast, platelet activation receptor expression of CD40L, CD62P, and PAC-1 were higher at 12 months versus 1 month. CONCLUSIONS: Our pilot study showed no attenuation of clopidogrel's effects on platelet aggregation with long-term administration. However, platelet activation receptor expression increased with time and should be further evaluated.
OBJECTIVES: This study was designed to evaluate the effects of long-term clopidogrel and aspirin administration on platelet aggregation, activation, and inflammation. BACKGROUND:Clopidogrel resistance was described in 15% to 30% of patients with short-term therapy, but its antiplatelet effects with long-term therapy is unknown. METHODS: We performed a prospective study of patients undergoing coronary stenting who were on aspirin for > or =5 days but not previously on clopidogrel. Clopidogrel 600 mg was given before stenting. Clopidogrel 75 mg/day and aspirin 325 mg/day were continued for 1 year. Light-transmittance aggregometry with 5-micromol/l adenosine diphosphate and 1-mmol/l arachidonic acid stimulation; VerifyNow clopidogrel and aspirin assays; platelet activation receptor expression of CD40L, CD62P, and PAC-1 (antibody against activated glycoprotein IIb/IIIa); and inflammatory markers of soluble CD40L and P-selectin, high-sensitivity C-reactive protein, interleukin-10, and interleukin-18 were measured at baseline; 1 day; and 1, 6, and 12 months. Our primary analysis compared light-transmittance aggregometry aggregation at 1 versus 12 months. RESULTS: We enrolled 26 patients who completed a 1-year follow-up. Maximal platelet adenosine diphosphate-stimulated aggregation was 61.8 +/- 25.9% at baseline, 22.1 +/- 18.3% at 1 day, 30.6 +/- 16.8% at 1 month, 29.0 +/- 13.3% at 6 months, and 26.7 +/- 13.6% at 12 months (p = 0.099 for 12 months vs. 1 month). VerifyNow clopidogrel platelet inhibition was similar at 12 months versus 1 month (38.9 +/- 19.7% vs. 45.6 +/- 26.7%, p = 0.578). Likewise, there was no difference in aspirin's effects on platelet aggregation at 12 months versus 1 month. In contrast, platelet activation receptor expression of CD40L, CD62P, and PAC-1 were higher at 12 months versus 1 month. CONCLUSIONS: Our pilot study showed no attenuation of clopidogrel's effects on platelet aggregation with long-term administration. However, platelet activation receptor expression increased with time and should be further evaluated.
Authors: Steven Haller; Satjit Adlakha; Grant Reed; Pamela Brewster; David Kennedy; Mark W Burket; William Colyer; Haifeng Yu; Dong Zhang; Joseph I Shapiro; Christopher J Cooper Journal: Clin J Am Soc Nephrol Date: 2011-08-04 Impact factor: 8.237
Authors: P C J Armstrong; P D Leadbeater; M V Chan; N S Kirkby; J A Jakubowski; J A Mitchell; T D Warner Journal: J Thromb Haemost Date: 2011-03 Impact factor: 5.824
Authors: P D M Leadbeater; N S Kirkby; S Thomas; A-R Dhanji; A T Tucker; G L Milne; J A Mitchell; T D Warner Journal: J Thromb Haemost Date: 2011-10 Impact factor: 5.824
Authors: Joanna J Wykrzykowska; Ascan Warnholtz; Peter de Jaeger; Nick Curzen; Keith G Oldroyd; Jean Philippe Collet; Jurrien M Ten Berg; Tessa Rademaker; Dick Goedhart; Jurgen Lissens; Peter-Paul Kint; Patrick W Serruys Journal: J Thromb Thrombolysis Date: 2009-11 Impact factor: 2.300
Authors: Nina A Hilkens; Ale Algra; L Jaap Kappelle; Philip M Bath; László Csiba; Peter M Rothwell; Jacoba P Greving Journal: Neurology Date: 2018-01-26 Impact factor: 9.910
Authors: Charlotte Grosdidier; Kelly D Blanz; Pierre Deharo; Denis Bernot; Marjorie Poggi; Delphine Bastelica; Dennis Wolf; Daniel Duerschmied; Michel Grino; Thomas Cuisset; Marie-Christine Alessi; Matthias Canault Journal: Res Pract Thromb Haemost Date: 2019-07-26